196 related articles for article (PubMed ID: 34544797)
21. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Van Swearingen AED; Siegel MB; Deal AM; Sambade MJ; Hoyle A; Hayes DN; Jo H; Little P; Dees EC; Muss H; Jolly T; Zagar TM; Patel N; Miller CR; Parker JS; Smith JK; Fisher J; Shah N; Nabell L; Nanda R; Dillon P; Abramson V; Carey LA; Anders CK
Breast Cancer Res Treat; 2018 Oct; 171(3):637-648. PubMed ID: 29938395
[TBL] [Abstract][Full Text] [Related]
22. Tumor lineage-specific immune response in brain metastatic disease: opportunities for targeted immunotherapy regimen?
Najjary S; Kros JM; de Koning W; Vadgama D; Lila K; Wolf J; Mustafa DAM
Acta Neuropathol Commun; 2023 Apr; 11(1):64. PubMed ID: 37061716
[TBL] [Abstract][Full Text] [Related]
23. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
Shawky H; Tawfik H
J Egypt Natl Canc Inst; 2014 Dec; 26(4):187-94. PubMed ID: 25294797
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy.
Leone JP; Lee AV; Brufsky AM
Cancer Med; 2015 Jul; 4(7):989-94. PubMed ID: 25756607
[TBL] [Abstract][Full Text] [Related]
25. Radiographic markers of breast cancer brain metastases: relation to clinical characteristics and postoperative outcome.
Michel A; Dinger T; Darkwah Oppong M; Rauschenbach L; Deuschl C; Ahmadipour Y; Pierscianek D; Wrede K; Hense J; Pöttgen C; Iannaccone A; Kimmig R; Sure U; Jabbarli R
Acta Neurochir (Wien); 2022 Feb; 164(2):439-449. PubMed ID: 34677686
[TBL] [Abstract][Full Text] [Related]
26. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis.
Wang S; Liang K; Hu Q; Li P; Song J; Yang Y; Yao J; Mangala LS; Li C; Yang W; Park PK; Hawke DH; Zhou J; Zhou Y; Xia W; Hung MC; Marks JR; Gallick GE; Lopez-Berestein G; Flores ER; Sood AK; Huang S; Yu D; Yang L; Lin C
J Clin Invest; 2017 Dec; 127(12):4498-4515. PubMed ID: 29130936
[TBL] [Abstract][Full Text] [Related]
27. Treatment strategies for breast cancer brain metastases.
Bailleux C; Eberst L; Bachelot T
Br J Cancer; 2021 Jan; 124(1):142-155. PubMed ID: 33250512
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive molecular biomarker identification in breast cancer brain metastases.
Schulten HJ; Bangash M; Karim S; Dallol A; Hussein D; Merdad A; Al-Thoubaity FK; Al-Maghrabi J; Jamal A; Al-Ghamdi F; Choudhry H; Baeesa SS; Chaudhary AG; Al-Qahtani MH
J Transl Med; 2017 Dec; 15(1):269. PubMed ID: 29287594
[TBL] [Abstract][Full Text] [Related]
29. Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.
Mounsey LA; Deal AM; Keith KC; Benbow JM; Shachar SS; Zagar T; Dees EC; Carey LA; Ewend MG; Anders CK
Clin Breast Cancer; 2018 Feb; 18(1):29-37. PubMed ID: 28867445
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-13 receptor alpha 2 as a marker of poorer prognosis in high-grade astrocytomas.
Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Otsuka Y; Yamaguchi M; Ohnishi H; Ohtaki S; Noshiro S; Ookawa S; Mikami T; Mikuni N; Honmou O
J Neurosurg Sci; 2018 Jun; 62(3):239-244. PubMed ID: 28079349
[TBL] [Abstract][Full Text] [Related]
31. Subtype switching in breast cancer brain metastases: a multicenter analysis.
Hulsbergen AFC; Claes A; Kavouridis VK; Ansaripour A; Nogarede C; Hughes ME; Smith TR; Brastianos PK; Verhoeff JJC; Lin NU; Broekman MLD
Neuro Oncol; 2020 Aug; 22(8):1173-1181. PubMed ID: 31970416
[TBL] [Abstract][Full Text] [Related]
32. FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis.
Cordero A; Kanojia D; Miska J; Panek WK; Xiao A; Han Y; Bonamici N; Zhou W; Xiao T; Wu M; Ahmed AU; Lesniak MS
Oncogene; 2019 Sep; 38(37):6445-6460. PubMed ID: 31324889
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-13 receptor α2 is a novel marker and potential therapeutic target for human melanoma.
Okamoto H; Yoshimatsu Y; Tomizawa T; Kunita A; Takayama R; Morikawa T; Komura D; Takahashi K; Oshima T; Sato M; Komai M; Podyma-Inoue KA; Uchida H; Hamada H; Fujiu K; Ishikawa S; Fukayama M; Fukuhara T; Watabe T
Sci Rep; 2019 Feb; 9(1):1281. PubMed ID: 30718742
[TBL] [Abstract][Full Text] [Related]
34. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
Thaci B; Brown CE; Binello E; Werbaneth K; Sampath P; Sengupta S
Neuro Oncol; 2014 Oct; 16(10):1304-12. PubMed ID: 24723564
[TBL] [Abstract][Full Text] [Related]
35. SNORA71B promotes breast cancer cells across blood-brain barrier by inducing epithelial-mesenchymal transition.
Duan S; Luo X; Zeng H; Zhan X; Yuan C
Breast Cancer; 2020 Nov; 27(6):1072-1081. PubMed ID: 32458152
[TBL] [Abstract][Full Text] [Related]
36. Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.
Wikman H; Sielaff-Frimpong B; Kropidlowski J; Witzel I; Milde-Langosch K; Sauter G; Westphal M; Lamszus K; Pantel K
PLoS One; 2012; 7(10):e47537. PubMed ID: 23118876
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Prognostic Factors Affecting the Brain Metastases Free Survival and Survival After Brain Metastases in Breast Cancer.
Xiao W; Li X; Yang A; Chen B; Zheng S; Zhang G; Deng W; Liao N
Front Oncol; 2020; 10():431. PubMed ID: 32309214
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
[TBL] [Abstract][Full Text] [Related]
39. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
Hegde M; Mukherjee M; Grada Z; Pignata A; Landi D; Navai SA; Wakefield A; Fousek K; Bielamowicz K; Chow KK; Brawley VS; Byrd TT; Krebs S; Gottschalk S; Wels WS; Baker ML; Dotti G; Mamonkin M; Brenner MK; Orange JS; Ahmed N
J Clin Invest; 2016 Aug; 126(8):3036-52. PubMed ID: 27427982
[TBL] [Abstract][Full Text] [Related]
40. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?
Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thézenas S; Jacot W
Int J Cancer; 2016 Nov; 139(10):2299-311. PubMed ID: 27464303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
